Format

Send to

Choose Destination
Ginekol Pol. 2019;90(10):571-576. doi: 10.5603/GP.2019.0099.

The role of nesfatin and selected molecular factors in various types of endometrial cancer.

Author information

1
Department of Perinatology and Gynecology, Poznan University of Medical Sciences, Poznan, Poland.
2
Department of Oncology, Gynaecological Oncology, Poznan University of Medical Sciences, Poznan, Poland. monika.szarszewska@gmail.com.
3
Department of Gynecology and Gynecologic Oncology, Medical University of Bialystok, Bialystok, Poland.
4
Department of Gyneacology and Obstetrics, Faculty of Health Science, Wroclaw Medical University, Wroclaw, Poland.
5
Medical School in Opole, Opole, Poland.
6
Department of Tumour Pathology and Prophylaxis, Poznan University of Medical Sciences, Greater Poland Cancer Centre, Poznan, Poland.
7
Medical University of Lodz, Gynecological-Oncology, Lodz, Poland.
8
Gynecological Endocrinology Department, Jagiellonian University Medical College, Krakow, Poland.
9
Department of Oncology, Gynaecological Oncology, Poznan University of Medical Sciences, Poznan, Poland.

Abstract

OBJECTIVES:

Endometrial cancers (ECs) are the most common gynaecological cancers in well developed countries. Diabetes and metabolic syndrome are among the biggest risk factors. Nesfatin-1, the adipokine derivative of NUCB2 (nucleobindin derivative 2) is linked to the clinical course of EC. Molecular factors, including mutations in MLH1 and MHS2 genes, c-MET and ARID1A are also related to prognosis in endometrial cancer.

MATERIAL AND METHODS:

Using sections of paraffin-embedded preparations and immunohistochemistry, the expression of NESF1, MLH1, MSH2,c-MET and ARID1A were examined.

RESULTS:

In this study on protein expression, EC tissues manifested (although insignificantly) an elevated expression of NESF-1 in type II EC. In type I EC, NESF-1 expression was significantly higher in G1 in comparison to G2 and G3 together. A significantly lower expression of MLH1 was demonstrated in type I EC.

CONCLUSIONS:

The most pronounced expression involved c-MET in all EC I and EC II tissues (in over 80% of cases). A tendency was detected for a high expression of NESF-1 in patients with type II EC, who also exhibited a high expression of MSH2.

KEYWORDS:

ARID1A; MLH1; MSH2; NESF-1; c-MET; endometrial cancer

PMID:
31686413
DOI:
10.5603/GP.2019.0099
Free full text

Supplemental Content

Full text links

Icon for Via Medica Medical Publishers
Loading ...
Support Center